89,570 results on '"Drug Resistance, Neoplasm"'
Search Results
2. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort.
- Author
-
Lansbergen, Marjolein F., Dings, Mark P.G., Manoukian, Paul, Fariña, Arantza, Waasdorp, Cynthia, Hooijer, Gerrit K.J., Verheij, Joanne, Koster, Jan, Zwijnenburg, Danny A., Wilmink, Johanna W., Medema, Jan Paul, Dijk, Frederike, van Laarhoven, Hanneke W.M., and Bijlsma, Maarten F.
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at metastatic stage and typically treated with fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX). Few patients benefit from this treatment. Molecular subtypes are prognostic in particularly resectable PDAC and might predict treatment response. This study aims to correlate molecular subtypes in metastatic PDAC with FOLFIRINOX responses using real-world data, providing assistance in counselling patients. We collected 131 RNA-sequenced metastatic biopsies and applied a network-based meta-analysis using published PDAC classifiers. Subsequent survival analysis was performed using the most suitable classifier. For validation, we developed an immunohistochemistry (IHC) classifier using GATA6 and keratin-17 (KRT17), and applied it to 86 formalin-fixed paraffin-embedded samples of advanced PDAC. Lastly, GATA6 knockdown models were generated in PDAC organoids and cell lines. We showed that the PurIST classifier was the most suitable classifier. With this classifier, classical tumors had longer PFS and OS than basal-like tumors (PFS: 216 vs. 78 days, p = 0.0002; OS: 251 vs. 195 days, p = 0.049). The validation cohort showed a similar trend. Importantly, IHC GATA6
low patients had significantly shorter survival with FOLFIRINOX (323 vs. 746 days, p = 0.006), but no difference in non-treated patients (61 vs. 54 days, p = 0.925). This suggests that GATA6 H-score predicts therapy response. GATA6 knockdown models did not lead to increased FOLFIRINOX responsiveness. These data suggest a predictive role for subtyping (transcriptomic and GATA6 IHC), though no direct causal relationship was found between GATA6 expression and chemoresistance. GATA6 immunohistochemistry should be seamlessly added to current diagnostics and integrated into upcoming clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Metabolic Reprogramming in Thyroid Cancer
- Author
-
Sang-Hyeon Ju, Minchul Song, Joung Youl Lim, Yea Eun Kang, Hyon-Seung Yi, and Minho Shong
- Subjects
thyroid neoplasms ,tyrosine kinase inhibitors ,drug resistance, neoplasm ,metabolic networks and pathways ,immunotherapy ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Thyroid cancer is a common endocrine malignancy with increasing incidence globally. Although most cases can be treated effectively, some cases are more aggressive and have a higher risk of mortality. Inhibiting RET and BRAF kinases has emerged as a potential therapeutic strategy for the treatment of thyroid cancer, particularly in cases of advanced or aggressive disease. However, the development of resistance mechanisms may limit the efficacy of these kinase inhibitors. Therefore, developing precise strategies to target thyroid cancer cell metabolism and overcome resistance is a critical area of research for advancing thyroid cancer treatment. In the field of cancer therapeutics, researchers have explored combinatorial strategies involving dual metabolic inhibition and metabolic inhibitors in combination with targeted therapy, chemotherapy, and immunotherapy to overcome the challenge of metabolic plasticity. This review highlights the need for new therapeutic approaches for thyroid cancer and discusses promising metabolic inhibitors targeting thyroid cancer. It also discusses the challenges posed by metabolic plasticity in the development of effective strategies for targeting cancer cell metabolism and explores the potential advantages of combined metabolic targeting.
- Published
- 2024
- Full Text
- View/download PDF
4. Fortschritte in der zielgerichteten Behandlung des nicht-kleinzelligen Lungenkarzinoms.
- Author
-
Ruge, Lea, John, Felix, Scharpenseel, Heather, and Wolf, Jürgen
- Abstract
Copyright of Innere Medizin (2731-7080) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
5. 钙蛋白酶 2 通过诱导三阴乳腺癌细胞上皮间质转化抵抗 紫杉醇的机制探讨.
- Author
-
陈聪, 吴元肇, 郑克思, 应文兵, and 胡逸人
- Abstract
Objective To investigate the role and mechanism of Calpain-2 in paclitaxel (PTX) resistance in triplenegative breast cancer cells. Methods Human triple negative breast cancer MDA-MB-231 cells were transfected with Calpain-2 plasmid and corresponding empty vector, and cells were used as the overexpression group and the empty vector group. The untransfected cells were used as the blank group. MTT assay was performed to detect the effect of PTX on the survival rate of each group of cells. Western blot assay was performed to detect the expression of Calpain-2, E-calmodulin (E-cadherin), N-cadherin, Vimentin, phosphorylated large tumour suppressor gene 1 (p-LATS1) and phosphorylated yesassociated protein (p-YAP). Immunofluorescence assay was performed to detect the distribution of YAP. YAP inhibitor XMU-MP-1 was added to intervene on the basis of overexpression of Calpain-2. The mediated effect of YAP on PTX resistance was observed. Results Compared with the empty vector group, the survival rate of cells increased after PTX treatment in the overexpression group, and the IC50 value increased (P<0.05). Compared with the empty vector group, Ncadherin and Vimentin protein expression were up-regulated, E-cadherin protein expression was down-regulated in the overexpression group (P<0.05), and p-LATS1 and p-YAP protein expression were up-regulated (P<0.01). YAP distribution in nucleus was reduced in the overexpression group. Compared with the overexpression group, N-cadherin and Vimentin protein expression were down-regulated and E-cadherin protein expression was up-regulated in the XMU-MP-1+ overexpression group (P<0.01). After PTX treatment, cell survival was reduced, and IC50 was lower in the XMU-MP-1+ overexpression group compared with the overexpression group (P<0.01). Conclusion Calpain-2 induces epithelial mesenchymal transition in triple-negative breast cancer cells via YAP, resulting in drug resistance to PTX. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. The study of FGFR3 ⁃ TACC3 fusion gene mediating pyruvate kinase M2 nuclear translocation to promote DNA damage repair in glioblastoma
- Author
-
REN Xiu⁃de, LI Tao, FAN Ji⁃kang, WANG Xi⁃sen, JIA Xiao⁃dan, and YANG Xue⁃jun
- Subjects
glioblastoma ,receptor, fibroblast growth factor, type 3 ,gene fusion ,pyruvate kinase ,dna repair ,temozolomide ,drug resistance, neoplasm ,cell proliferation ,immunoblotting ,tumor cells, cultured ,disease models, animal ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Objective To explore the mechanism of FGFR3⁃TACC3 (F3⁃T3) fusion gene mediating DNA damage repair through promoting pyruvate kinase M2 (PKM2)'s nuclear translocation in glioblastoma. Methods The lentiviral transfection technology was used to constructed stable transitional cell lines U87MG cells and U251MG cells that stably expressing F3 ⁃ T3 and empty vector. In vivo glioblastoma model was constructed by intracranial in situ tumor implantation in athymic mice, and the tumorigenic ability of F3⁃T3 transfected cells in athymic mice of each treatment group was observed by small⁃animal in vivo imaging system. Bioinformatics analysis was performed to analyze gene microarray data exploring the possible biological functions of F3 ⁃ T3 mediating chemoresistance and identify the relationship between survival expectations and PKM2 expression levels in glioblastoma patients from The Cancer Genome Atlas (TCGA) database. Transient transfection of small interference RNA (siRNA) was used to knock down the expression of PKM2 in the F3 ⁃ T3 transfected cells. Proliferative activity of U87MG and U251MG cells treated with different concentrations of temozolomide (TMZ), transfected with siRNA, and TMZ in combination with Compound 3k, a PKM2 inhibitor, was observed in CCK ⁃ 8 cell proliferation assays. Nuclear and cytoplasmic proteins were extracted separately and PKM2 protein expression was observed in whole cell extract, cytoplasmic extract and cytosolic extract after TMZ treatment. Relative expression of PKM2, relative expression of cytosolic phosphorylated histone H2AX (p⁃H2AX) and relative expression of siRNA knockdown PKM2 gene in U87MG and U251MG cells stably expressing the F3 ⁃ T3 fusion gene, detected by Western blotting. Results 1) CCK⁃8 cell proliferation assay showed that the survival rate of U87MG cells in the F3 ⁃ T3 transfected group was higher than that in the empty vector transfected group after treatment with TMZ 640, 320, 160, 80, 40 μmol/L (P = 0.000, 0.000, 0.000, 0.000, 0.004, 0.010), and the survival rate of U251MG cells in the F3 ⁃ T3 transfected group was also higher than that in the empty vector transfected group after TMZ 640, 320, 160, 80, 40, 20, 5 μmol/L (P = 0.000, 0.000, 0.000, 0.002, 0.001, 0.002); the survial rate of U87MG cells in the si⁃PKM2⁃1009 transfected group was lower than that of F3 ⁃ T3 transfected group after TMZ 640, 320, 160, 80, 40, 20, 10, 5, 2.50 μmol/L, the survival rate of U251MG cells in the si⁃PKM2⁃1377 transfected group was also lower than that in F3⁃T3 transfected group after TMZ 640, 320, 160, 80, 40, 20, 5 μmol/L (P = 0.000, 0.000, 0.002, 0.000, 0.002, 0.048, 0.042); and the survival rate of U87MG cells in TMZ + Compound 3k group was lower than TMZ group after TMZ 640, 320, 160, 80, 40, 20 μmol/L (P = 0.000, 0.000, 0.000, 0.000, 0.001, 0.002), and the survival rate of U251MG cells in TMZ + Compound 3k group after treatment with high concentrations of TMZ (640, 320, 160, 80 and 40 μmol/L) was also lower than TMZ group (P = 0.000, 0.000, 0.000, 0.000, 0.003), while the survival rate of U251MG cells in TMZ + Compound 3k group after treatment with low concentrations of TMZ (10, 5 and 2.50 μmol/L) was higher than that of TMZ group (P = 0.000, 0.000, 0.006). 2) An animal model of glioblastoma showed the presence of TMZ resistance in homozygous mice. 3) Bioinformatic analysis showed that the biological function of F3⁃T3 was significantly enriched in the DNA repair pathway (P = 0.000). Survival and overall survival of glioblastoma patients in the TCGA database were lower in the PKM2 high expression group than in the low expression group (P < 0.05). 4) Western blotting showed that the relative expression of p⁃H2AX in U87MG (P = 0.000, 0.000, 0.004) and U251MG (P = 0.000, 0.007, 0.005) cells in the F3 ⁃ T3 transfected group were lower than those in the empty vector transfected group after TMZ treatment for 48 h and then medium change for 24, 36 and 48 h. PKM2 protein incorporation into the nucleus was observed in both U87MG and U251MG cells in the F3⁃T3 transfected group after TMZ treatment, whereas it was not observed in cells in the empty vector transfected group; si⁃PKM2⁃1009 and si⁃ PKM2⁃1377 knocked down the relative expression of p⁃H2AX in U87MG (P = 0.000, 0.001, 0.006) and U251MG (P = 0.000, 0.000, 0.000) cells, respectively. Conclusions In the presence of TMZ, F3 ⁃ T3 promotes PKM2's nuclear translocation and activates DNA damage repair pathways, which in the eventually results resistance of glioblastoma cell to TMZ. PKM2 inhibitors can compromise the resistance glioblastoma cells stably expressing F3⁃T3 fusion gene to TMZ.
- Published
- 2023
- Full Text
- View/download PDF
7. 白藜芦醇通过BRD4调控Wnt/β-catenin通路逆转胶质瘤 细胞替莫唑胺耐药的机制研究.
- Author
-
李振江, 孙德超, 孔晨旭, 耿亚东, 徐晨阳, and 丁炳谦
- Abstract
Objective To explore whether the effect of resveratrol in reversing temozolomide (TMZ) resistance in glioma cells was related to the regulation of bromodomain-containing protein 4 (BRD4) and Wnt/β -catenin pathways. Methods Human glioma TMZ low-sensitivity cell line (U138), high-sensitivity cell line (U251) and drug-resistant cell line (T98G) were obtained, and Western blot assay was performed to detect the protein expressions of BRD4, Wnt3a, βcatenin and TMZ drug resistance protein (MGMT). T98G cell line was taken and divided into the control group 1 (adding 100 µmoL/L TMZ), the RES1 group (adding 50 µmoL/L RES) and RES+TMZ group (adding 100 µmoL/L TMZ and 50 µmoL/L RES). Cell proliferation and apoptosis were measured by CCK-8 method and flow cytometry. Protein expressions of BRD4, Wnt3a, β-catenin and MGMT were measured by Western blot assay. In order to analyze the effect of BRD4 overexpression on TMZ resistance, on the basis of adding 100 µmoL/L TMZ, T98G cells were transfected with BRD4 overexpression plasmid (pcDNA BRD4) or added 50 µmoL/L RES, and cells were divided into the pcDNA NC group, the pcDNA BRD4 group, the RES2 group and the RES+pcDNA BRD4 group. In order to verify the regulatory effect of BRD4 on Wnt3a/β -catenin pathway, on the basis of adding 100 µmoL/L TMZ, BRD4 inhibitor JQ1 and the Wnt3a/β-catenin pathway activator LiCl were added, and cells were divided into the control 2 groups, the JQ1 group and the JQ1+LiCl group. T98G cells were inoculated into the left scapular region of nude mice, and treated with RES, TMZ and/or JQ1. Protein expressions of Ki67,BRD4, MGMT and Wnt3a/β -catenin in tumor were measured. Results Compared with the high-susceptibility strain (U251), the expressions of BRD4, Wnt3a, β -catenin and MGMT increased in sequence in the low-susceptibility strain (U138) and the drug-resistant strain (T98G) (P<0.05). Compared with the control group 1, RES intervention could inhibit the expression and proliferation of BRD4, Wnt3a/β -catenin and MGMT proteins in T98G cells, promote apoptosis and reverse cell drug resistance (P<0.05). PcDNA BRD4 could reverse the anti-proliferative and pro-apoptotic effects of RES. BRD4 inhibitor JQ1 could inhibit the expression and proliferation of BRD4, Wnt3a/β-catenin and MGMT proteins in T98G cells, and promote apoptosis (P<0.05). LiCl could reverse the anti-proliferative and pro-apoptotic effects of JQ1. RES alone or in combination with JQ1 could activate the inhibitory effect of TMZ on Wnt3a/β-catenin pathway, MGMT expression and cell proliferation in tumors (P<0.05). Conclusion RES can reverse TMZ resistance of glioma T98G cells by downregulating BRD4 and thereby inhibiting the activation of Wnt3a/β-catenin pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms.
- Author
-
Scheffler, Matthias, Michels, Sebastian, and Nogova, Lucia
- Abstract
Copyright of Der Internist is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
9. LPCAT2-mediated lipid droplet production supports pancreatic cancer chemoresistance and cell motility.
- Author
-
Lin Y, Zhang X, Wang Y, and Yao W
- Subjects
- Humans, Animals, Cell Line, Tumor, Mice, Male, Female, Mice, Nude, Xenograft Model Antitumor Assays, STAT5 Transcription Factor metabolism, Middle Aged, Mice, Inbred BALB C, Gene Expression Regulation, Neoplastic drug effects, Cell Proliferation drug effects, Cell Movement drug effects, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, Drug Resistance, Neoplasm, 1-Acylglycerophosphocholine O-Acyltransferase metabolism, 1-Acylglycerophosphocholine O-Acyltransferase genetics, Lipid Droplets metabolism, Deoxycytidine analogs & derivatives, Deoxycytidine pharmacology, Deoxycytidine therapeutic use, Gemcitabine
- Abstract
Lipid droplet (LD) accumulation is one of the features in various tumors, whereas the significance of LD accumulation in pancreatic cancer progression remains unclear under chemotherapeutic condition. Since chemoresistance towards gemcitabine (GEM) is an obstacle for clinical therapy of pancreatic cancer, we sought to investigate the contribution of LD accumulation to GEM resistance. Herein, triacsin C (an inhibitor of LD production) dampened the proliferation, migration, and invasion of pancreatic cancer cells. The inhibition of LD accumulation induced by triacsin C or silencing of perilipin 2 (a marker of LD) sensitized cells to GEM treatment. Next, 75 paraffin-embedded samples and 5 pairs of frozen samples from pancreatic cancer patients were obtained for the detection of lysophosphatidylcholine acyltransferase 2 (LPCAT2; a LD-located enzyme contributing phosphatidylcholine synthesis) expression. The results revealed that LPCAT2 was upregulated in pancreatic cancer tissues, and its expression was correlated with clinical parameters and the basal LD content of cancer cell lines. Loss of LPCAT2 repressed the LD accumulation, GEM resistance, and cell motility. The enhancement of chemotherapy sensitivity was further confirmed in a xenograft model of mice in vivo. The carcinogenesis role of LPCAT2 was at least partly mediated by the LD accumulation. Then, signal transducer and activator of transcription 5B (STAT5B) activated the transcription of LPCAT2. Both LPCAT2 downregulation and triacsin C reversed the STAT5B-induced potentiation of malignant phenotypes in pancreatic cancer cells. In conclusion, LPCAT2-mediated lipid droplet production supported pancreatic cancer chemoresistance and cell motility, which was triggered by STAT5B., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Enhanced desmosome assembly driven by acquired high-level desmoglein-2 promotes phenotypic plasticity and endocrine resistance in ER + breast cancer.
- Author
-
Liu B, Liu Y, Yang S, Ye J, Hu J, Chen S, Wu S, Liu Q, Tang F, Liu Y, He Y, Du Y, Zhang G, Guo Q, and Yang C
- Subjects
- Humans, Female, Animals, Mice, Fulvestrant pharmacology, Antineoplastic Agents, Hormonal pharmacology, Receptors, Estrogen metabolism, Cell Line, Tumor, Phenotype, Plakophilins metabolism, Plakophilins genetics, Cell Plasticity drug effects, Xenograft Model Antitumor Assays, MCF-7 Cells, Gene Expression Regulation, Neoplastic, gamma Catenin, Desmoglein 2 metabolism, Desmoglein 2 genetics, Breast Neoplasms pathology, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms drug therapy, Drug Resistance, Neoplasm, Desmosomes metabolism, Wnt Signaling Pathway
- Abstract
Acquired resistance to endocrine treatments remains a major clinical challenge. In this study, we found that desmoglein-2 (DSG2) plays a major role in acquired endocrine resistance and cellular plasticity in ER
+ breast cancer (BC). By analysing the well-established fulvestrant-resistant ER+ BC model using single-cell RNA-seq, we revealed that ER inhibition leads to a specific increase in DSG2 in cancer cell populations, which in turn enhances desmosome formation in vitro and in vivo and cell phenotypic plasticity that promotes resistance to treatment. DSG2 depletion reduced tumorigenesis and metastasis in fulvestrant-resistant xenograft models and promoted fulvestrant efficiency. Mechanistically, DSG2 forms a desmosome complex with JUP and Vimentin and triggers Wnt/PCP signalling. We showed that elevated DSG2 levels, along with reduced ER levels and an activated Wnt/PCP pathway, predicted poor survival, suggesting that a DSG2high signature could be exploited for therapeutic interventions. Our analysis highlighted the critical role of DSG2-mediated desmosomal junctions following antiestrogen treatment., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
11. Cracking the code of Annexin A1-mediated chemoresistance.
- Author
-
Ganesan T, Sinniah A, Ramasamy TS, and Alshawsh MA
- Subjects
- Humans, Signal Transduction, Animals, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Epithelial-Mesenchymal Transition, Drug Resistance, Neoplasm, Annexin A1 metabolism, Annexin A1 genetics, Neoplasms drug therapy, Neoplasms metabolism, Neoplasms pathology
- Abstract
The annexin superfamily protein, Annexin A1, initially recognized for its glucocorticoid-induced phospholipase A2-inhibitory activities, has emerged as a crucial player in diverse cellular processes, including cancer. This review explores the multifaceted roles of Anx-A1 in cancer chemoresistance, an area largely unexplored. Anx-A1's involvement in anti-inflammatory processes, its complex phosphorylation patterns, and its context-dependent switch from anti-to pro-inflammatory in cancer highlights its intricate regulatory mechanisms. Recent studies highlight Anx-A1's paradoxical roles in different cancers, exhibiting both up- and down-regulation in a tissue-specific manner, impacting different hallmark features of cancer. Mechanistically, Anx-A1 modulates drug efflux transporters, influences cancer stem cell populations, DNA damages and participates in epithelial-mesenchymal transition. This review aims to explore Anx-A1's role in chemoresistance-associated pathways across various cancers, elucidating its impact on survival signaling cascades including PI3K/AKT, MAPK/ERK, PKC/JNK/P-gp pathways and NFκ-B signalling. This review also reveals the clinical implications of Anx-A1 dysregulation in treatment response, its potential as a prognostic biomarker, and therapeutic targeting strategies, including the promising Anx-A1 N-terminal mimetic peptide Ac2-26. Understanding Anx-A1's intricate involvement in chemoresistance offers exciting prospects for refining cancer therapies and improving treatment outcomes., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
- Author
-
Ning T, Li D, Deng T, Bai Y, Chen Y, Wang Z, Hu B, Ba Y, and Lu W
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prospective Studies, Protein Kinase Inhibitors therapeutic use, Immune Checkpoint Inhibitors therapeutic use, B7-H1 Antigen antagonists & inhibitors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Adult, Immunotherapy methods, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized therapeutic use, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular pathology, Esophageal Squamous Cell Carcinoma drug therapy, Esophageal Squamous Cell Carcinoma pathology, Esophageal Squamous Cell Carcinoma immunology, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Liver Neoplasms immunology, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Esophageal Neoplasms immunology
- Abstract
Background: Effective systemic therapy remains limited for advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC), particularly after prior failed treatment with immune checkpoint inhibitors (ICIs). Theoretically, a combination of tyrosine kinase inhibitors (TKIs) with ICIs may restore immunotherapy sensitivity., Methods: In this phase 1b study, patients received AL2846, an antiangiogenic TKI with multiple targets (c-MET, VEGFR1, c-KIT, Axl, RET, KDR, and VEGFR3), in combination with an anti-PD-L1 antibody (TQB2450) until disease progression, intolerable toxicity, death, or discontinuation for any cause. The primary end points included overall response rate (ORR) and safety, with secondary end points encompassing progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response., Results: Between November 2021 and September 2022, 18 patients with ESCC and 15 patients with HCC, whose ORR was 11.1% (95% confidence interval [CI], 3.1%-32.8%) and 0%, respectively, were enrolled. Adverse events (AEs) of any grade and treatment-related AEs were documented in 32 patients (97.0%) and 31 patients (93.9%), respectively. Grade 3 or higher AEs were observed in 10 patients (30.3%), with vomiting (6.1%) and infectious pneumonia (9.1%) being the most prevalent. Median PFS and OS values were 3.22 months (95% CI, 1.35-5.68 months) and 5.98 months (95% CI, 3.71-8.87 months), respectively, in patients with ESCC, and 5.55 months (95% CI, 2.66 months to not evaluable [NE]) and 16.72 months (95% CI, 4.86 months to NE), respectively, in patients with HCC. The DCRs were 66.7% (95% CI, 43.75%-83.72%) in patients with ESCC and 73.3% (95% CI, 48.05%-89.10%) in patients with HCC., Conclusions: Combined TQB2450 and AL2846 therapy exhibited a favorable safety profile in immunotherapy-refractory patients with advanced ESCC and HCC., (© 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)
- Published
- 2024
- Full Text
- View/download PDF
13. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.
- Author
-
Stieglitz E, Lee AG, Angus SP, Davis C, Barkauskas DA, Hall D, Kogan SC, Meyer J, Rhodes SD, Tasian SK, Xuei X, Shannon K, Loh ML, Fox E, and Weigel BJ
- Subjects
- Humans, Male, Female, Infant, Child, Preschool, Child, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local drug therapy, Hematopoietic Stem Cell Transplantation, Treatment Outcome, Pyridones therapeutic use, Pyridones pharmacology, Pyrimidinones therapeutic use, Pyrimidinones pharmacology, Leukemia, Myelomonocytic, Juvenile drug therapy, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors pharmacology
- Abstract
Juvenile myelomonocytic leukemia (JMML) is a hematologic malignancy of young children caused by mutations that increase Ras signaling output. Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment, but patients with relapsed or refractory (advanced) disease have dismal outcomes. This phase II trial evaluated the safety and efficacy of trametinib, an oral MEK1/2 inhibitor, in patients with advanced JMML. Ten infants and children were enrolled, and the objective response rate was 50%. Four patients with refractory disease proceeded to HSCT after receiving trametinib. Three additional patients completed all 12 cycles permitted on study and continue to receive off-protocol trametinib without HSCT. The remaining three patients had progressive disease with two demonstrating molecular evolution by the end of cycle 2. Transcriptomic and proteomic analyses provided novel insights into the mechanisms of response and resistance to trametinib in JMML. ClinicalTrials.gov Identifier: NCT03190915. Significance: Trametinib was safe and effective in young children with relapsed or refractory JMML, a lethal disease with poor survival rates. Seven of 10 patients completed the maximum 12 cycles of therapy or used trametinib as a bridge to HSCT and are alive with a median follow-up of 24 months. See related commentary by Ben-Crentsil and Padron, p. 1574., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
14. PRKDC Induces Chemoresistance in Osteosarcoma by Recruiting GDE2 to Stabilize GNAS and Activate AKT.
- Author
-
Zhang W, Li W, Yin C, Feng C, Liu B, Xu H, Jin X, Tu C, and Li Z
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Mice, Nude, Antibiotics, Antineoplastic pharmacology, Female, Cell Proliferation drug effects, Osteosarcoma drug therapy, Osteosarcoma pathology, Osteosarcoma metabolism, Osteosarcoma genetics, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-akt metabolism, Doxorubicin pharmacology, Bone Neoplasms drug therapy, Bone Neoplasms pathology, Bone Neoplasms metabolism, Bone Neoplasms genetics, Chromogranins genetics, Chromogranins metabolism, GTP-Binding Protein alpha Subunits, Gs metabolism, GTP-Binding Protein alpha Subunits, Gs genetics, Xenograft Model Antitumor Assays
- Abstract
Chemoresistance is one of the major causes of poor prognosis in osteosarcoma. Alternative therapeutic strategies for osteosarcoma are limited, indicating that increasing sensitivity to currently used chemotherapies could be an effective approach to improve patient outcomes. Using a kinome-wide CRISPR screen, we identified PRKDC as a critical determinant of doxorubicin (DOX) sensitivity in osteosarcoma. The analysis of clinical samples demonstrated that PRKDC was hyperactivated in osteosarcoma, and functional experiments showed that the loss of PRKDC significantly increased sensitivity of osteosarcoma to DOX. Mechanistically, PRKDC recruited and bound GDE2 to enhance the stability of protein GNAS. The elevated GNAS protein levels subsequently activated AKT phosphorylation and conferred resistance to DOX. The PRKDC inhibitor AZD7648 and DOX synergized and strongly suppressed the growth of osteosarcoma in mouse xenograft models and human organoids. In conclusion, the PRKDC-GDE2-GNAS-AKT regulatory axis suppresses DOX sensitivity and comprises targetable candidates for improving the efficacy of chemotherapy in osteosarcoma. Significance: Targeting PRKDC suppresses AKT activation and increases sensitivity to doxorubicin in osteosarcoma, which provides a therapeutic strategy for overcoming chemoresistance., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
15. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
- Author
-
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, and Martín García-Sancho A
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Adult, Aged, 80 and over, Deoxycytidine analogs & derivatives, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Gemcitabine, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Drug Resistance, Neoplasm, Rituximab administration & dosage, Rituximab adverse effects, Oxaliplatin administration & dosage, Oxaliplatin adverse effects, Treatment Outcome, Spain epidemiology, Pyrimidines administration & dosage, Pyrimidines adverse effects, Pyrimidines therapeutic use, Adenine analogs & derivatives, Adenine administration & dosage, Piperidines administration & dosage, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
- Abstract
Purpose: This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL)., Patients and Methods: The IBDCL trial (NCT02692248) included patients with histologic diagnosis of non-GCB DLBCL with relapsed or refractory disease and non-candidates for stem-cell transplantation. Patients received an induction treatment consisting of six or eight cycles of R-GemOx at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years. The primary objective was to evaluate the overall response rate after four cycles., Results: Sixty-four patients were included, 72% of them refractory to the last regimen. The overall response rate and complete remission rate after the fourth cycle were 53% [95% confidence interval (CI), 41-65] and 34% (95% CI, 24-46), respectively. Twenty-four (37%) patients started maintenance, and 7 (11%) completed the planned 2 years. After a median follow-up of 29.7 months (range: 0.4-48.6), the estimated 2-year progression-free survival and overall survival were 18% (95% CI, 8-28) and 26% (95% CI, 14-37), respectively. The most common grade ≥3 treatment-related adverse events were thrombocytopenia (44%), neutropenia (30%), and anemia (14%). Grade ≥3 infectious and cardiovascular treatment-related adverse events were reported in 6 (9%) and 1 (2%) patient, respectively., Conclusions: Ibrutinib in combination with R-GemOx, followed by ibrutinib maintenance, demonstrated encouraging antitumor activity with durable responses and a manageable toxicity in patients with non-GCB DLBCL., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
16. TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic Resistance.
- Author
-
Johansen AM, Forsythe SD, McGrath CT, Barker G, Jimenez H, Paluri RK, and Pasche BC
- Subjects
- Humans, Tumor Microenvironment drug effects, Animals, Immunotherapy methods, Transforming Growth Factor beta metabolism, Transforming Growth Factor beta antagonists & inhibitors, Colorectal Neoplasms drug therapy, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Colorectal Neoplasms genetics, Drug Resistance, Neoplasm, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms pathology, Signal Transduction drug effects
- Abstract
TGFβ is a pleiotropic signaling pathway that plays a pivotal role in regulating a multitude of cellular functions. TGFβ has a dual role in cell regulation where it induces growth inhibition and cell death; however, it can switch to a growth-promoting state under cancerous conditions. TGFβ is upregulated in colorectal cancer and pancreatic cancer, altering the tumor microenvironment and immune system and promoting a mesenchymal state. The upregulation of TGFβ in certain cancers leads to resistance to immunotherapy, and attempts to inhibit TGFβ expression have led to reduced therapeutic resistance when combined with chemotherapy and immunotherapy. Here, we review the current TGFβ inhibitor drugs in clinical trials for pancreatic and colorectal cancer, with the goal of uncovering advances in improving clinical efficacy for TGFβ combinational treatments in patients. Furthermore, we discuss the relevance of alterations in TGFβ signaling and germline variants in the context of personalizing treatment for patients who show lack of response to current therapeutics., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
17. Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study.
- Author
-
Xu Y, Xiong F, Li H, Zheng H, Jiang J, Li Q, Li G, Zhao W, Li R, Li J, Xie R, An R, Zhang H, and Gao Q
- Subjects
- Adult, Female, Humans, Middle Aged, Albumins administration & dosage, Albumins therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Biomarkers, Tumor genetics, Molecular Targeted Therapy, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Poly(ADP-ribose) Polymerase Inhibitors administration & dosage, Prospective Studies, Multicenter Studies as Topic, Clinical Trials, Phase II as Topic, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab administration & dosage, Bevacizumab therapeutic use, Carcinoma, Ovarian Epithelial drug therapy, Drug Resistance, Neoplasm, Neoplasm Recurrence, Local drug therapy, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Paclitaxel administration & dosage
- Abstract
Background: Platinum-resistant, recurrent ovarian cancer has an abysmal prognosis with limited treatment options. Poly-(ADP-ribose)-polymerase (PARP), angiogenesis, and immune checkpoint inhibitors might improve the outcomes of platinum-resistant, recurrent ovarian cancer, but accurate patient selections for those therapies remain a significant clinical challenge., Primary Objective: To evaluate the efficacy and safety of biomarker-driven combinatorial therapies of pamiparib, tislelizumab, bevacizumab, and nab-paclitaxel in platinum-resistant, recurrent ovarian cancer., Study Hypothesis: A precision medicine combination of PARP inhibitors, anti-angiogenic therapy, immunotherapy, and chemotherapy will improve disease outcomes of platinum-resistant, recurrent ovarian cancer by accounting for genomic and immunologic features., Trial Design: The BRIGHT Trial is a prospective, open-label, multicenter, phase II, umbrella study planning to enroll 160 patients with serous, endometrioid, or clear cell platinum-resistant, recurrent ovarian cancer from 11 clinical centers in China. Patients are assigned to one of three experimental arms based on biomarkers. Patients with BRCA1/2 mutations will receive pamiparib plus bevacizumab (arm 1, n=40) regardless of CD8
+ tumor-infiltrating lymphocytes count. Patients with wild-type BRCA1/2 ( BRCAwt ) and ≥3 CD8+ tumor-infiltrating lymphocytes count will receive the combination of tislelizumab, bevacizumab, and nab-paclitaxel (arm 2, n=50), while BRCAwt patients with <3 CD8+ tumor-infiltrating lymphocytes count will receive bevacizumab plus dose-dense nab-paclitaxel (arm 3, n=50). After completing patient enrollment in arm 2, another 20 BRCAwt patients with ≥3 CD8+ tumor-infiltrating lymphocytes count will be included as an arm 2 expansion. Treatment will continue until disease progression or intolerable toxicity, and all adverse events will be recorded., Major Inclusion/exclusion Criteria: Eligible patients include those aged ≥18 with serous, endometrioid, or clear cell ovarian cancer, platinum-resistant recurrence, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1., Primary Endpoint: Objective response rate (ORR) assessed by the investigators by the RECIST 1.1 criteria., Sample Size: 160 patients., Estimated Dates for Completing Accrual and Presenting Results: Recruitment is estimated to be completed by 2024 and results may be published by 2027., Trial Registration: ClinicalTrials.gov: NCT05044871., Competing Interests: Competing interests: None declared., (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF
18. Multi-task deep latent spaces for cancer survival and drug sensitivity prediction.
- Author
-
Rintala TJ, Napolitano F, and Fortino V
- Subjects
- Humans, Precision Medicine methods, Algorithms, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Cell Line, Tumor, Drug Resistance, Neoplasm, Computational Biology methods, Neoplasms drug therapy, Deep Learning
- Abstract
Motivation: Cancer is a very heterogeneous disease that can be difficult to treat without addressing the specific mechanisms driving tumour progression in a given patient. High-throughput screening and sequencing data from cancer cell-lines has driven many developments in drug development, however, there are important aspects crucial to precision medicine that are often overlooked, namely the inherent differences between tumours in patients and the cell-lines used to model them in vitro. Recent developments in transfer learning methods for patient and cell-line data have shown progress in translating results from cell-lines to individual patients in silico. However, transfer learning can be forceful and there is a risk that clinically relevant patterns in the omics profiles of patients are lost in the process., Results: We present MODAE, a novel deep learning algorithm to integrate omics profiles from cell-lines and patients for the purposes of exploring precision medicine opportunities. MODAE implements patient survival prediction as an additional task in a drug-sensitivity transfer learning schema and aims to balance autoencoding, domain adaptation, drug-sensitivity prediction, and survival prediction objectives in order to better preserve the heterogeneity between patients that is relevant to survival. While burdened with these additional tasks, MODAE performed on par with baseline survival models, but struggled in the drug-sensitivity prediction task. Nevertheless, these preliminary results were promising and show that MODAE provides a novel AI-based method for prioritizing drug treatments for high-risk patients., Availability and Implementation: https://github.com/UEFBiomedicalInformaticsLab/MODAE., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
19. Macrophage-induced Expression of TonEBP/NFAT5 Is Associated With Gefitinib Resistance and Migration in PC-9 Cells.
- Author
-
Song HJ, Sharma S, Kim T, Kim YH, Kim SJ, Kang MW, and Lee SD
- Subjects
- Humans, Cell Line, Tumor, ErbB Receptors metabolism, ErbB Receptors genetics, Apoptosis drug effects, Transcription Factors metabolism, Transcription Factors genetics, Antineoplastic Agents pharmacology, Culture Media, Conditioned pharmacology, Protein Kinase Inhibitors pharmacology, Coculture Techniques, Erlotinib Hydrochloride pharmacology, Gene Expression Regulation, Neoplastic drug effects, Gefitinib pharmacology, Cell Movement drug effects, Drug Resistance, Neoplasm, Macrophages metabolism, Macrophages drug effects, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms pathology, Lung Neoplasms metabolism, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Background/aim: Macrophages prevail in the microenvironment of several tumors, including non-small-cell lung cancer (NSCLC), where they secrete pro-tumorigenic factors that contribute to cancer progression. This study investigated the role of macrophages on the resistance of epidermal growth factor receptor (EGFR)-mutated NSCLC cells to tyrosine kinase inhibitors (TKIs)., Materials and Methods: EGFR-mutated cell lines PC-9 and HCC827 were cocultured with macrophages and treated with TKIs (erlotinib and gefitinib). The effects of the macrophage-conditioned medium (macrophage CM) on gefitinib resistance and cell migration were also evaluated., Results: Co-culture with macrophages significantly enhanced the resistance to erlotinib and gefitinib in PC-9 and HCC827 cells compared to that in cells cultured independently. Macrophage CM markedly induced gefitinib resistance in PC-9 cells, with maximum resistance observed at 50% CM concentration. This resistance persisted for up to 48 h post-CM removal. Macrophage CM inhibited gefitinib-induced apoptosis, as evidenced by the decreased expression of cleaved caspase-3, PARP, and BIM. Additionally, macrophage CM increased the migration ability of PC-9 cells, as shown by the wound healing and transwell migration assays. Studies have shown that TonEBP is crucial in cancer metastasis and drug resistance; we found that inhibition of TonEBP/NFAT5 expression reduced gefitinib resistance and migration in macrophage CM-induced PC-9 cells, indicating its role as mediator of these effects., Conclusion: Macrophages contribute to TKI resistance and enhance the migration of EGFR-mutated NSCLC cells through mechanisms involving TonEBP/NFAT5. Therefore, targeting TonEBP/NFAT5 represents a potential therapeutic strategy for overcoming macrophage-induced TKI resistance in NSCLC cells., (Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.
- Author
-
Blay JY, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, Bompas E, Verret B, Ray-Coquard I, Salas S, Henon C, Honoré C, Brahmi M, Dufresne A, Pracht M, Hervieu A, Penel N, Bertucci F, Rios M, Saada-Bouzid E, Soibinet P, Perol D, Chabaud S, Italiano A, and Cesne AL
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Follow-Up Studies, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, France, Gastrointestinal Neoplasms drug therapy, Gastrointestinal Neoplasms pathology, Gastrointestinal Neoplasms mortality, Progression-Free Survival, Adult, Time Factors, Drug Resistance, Neoplasm, Withholding Treatment statistics & numerical data, Drug Administration Schedule, Gastrointestinal Stromal Tumors drug therapy, Gastrointestinal Stromal Tumors pathology, Gastrointestinal Stromal Tumors mortality, Imatinib Mesylate administration & dosage, Imatinib Mesylate therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes of patients with advanced GIST stopping imatinib in the BFR14 trial., Methods: BFR14, an open-label, randomised, phase 3 trial, was done in 17 comprehensive cancer centres or hospitals across France. Patients with advanced GIST aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-3, no previous treatment with imatinib, and no previous malignancy were eligible. Patients were treated with oral imatinib 400 mg daily. Patients with a complete or partial response, or stable disease, according to Response Evaluation Criteria in Solid Tumours (1.0) at 1 year, 3 years, and 5 years from the start of treatment were randomly assigned (1:1) to treatment discontinuation until progression (interruption group) or treatment continuation until progression (continuation group). Randomisation was done centrally with computer-generated permuted blocks of two and six patients stratified by participating centre and presence or absence of residual disease on CT scan. The primary endpoint was progression-free survival. Secondary endpoints included time to imatinib resistance and overall survival. Analyses were conducted on an intention-to-treat basis in all randomly assigned patients who were not lost to follow-up. This trial is registered with ClinicalTrial.gov, NCT00367861., Findings: Between May 12, 2003, and March 16, 2004, after 1 year of imatinib, 32 patients were randomly assigned to the interruption group and 26 to the continuation group. Between June 13, 2005, and May 30, 2007, after 3 years of imatinib, 25 patients were randomly assigned to the interruption group and 25 to the continuation group. Between Nov 9, 2007, and July 12, 2010, after 5 years of imatinib, 14 patients were randomly assigned to the interruption group and 13 to the continuation group. Median follow-up was 235·2 months (IQR 128·8-236·6) after the 1-year randomisation, 200·9 months (190·2-208·4) after the 3-year randomisation, and 164·5 months (134·4-176·4) after the 5-year randomisation. Median progression-free survival in the interruption group versus the continuation group after 1 year of imatinib was 6·1 months (95% CI 2·5-10·1) versus 27·8 months (19·5-37·9; hazard ratio [HR] 0·36 [95% CI 0·20-0·64], log-rank p=0·0003), after 3 years of imatinib was 7·0 months (3·5-11·7) versus 67·0 months (48·8-85·6; 0·15 [0·07-0·32], log-rank p<0·0001), and after 5 years of imatinib was 12·0 months (9·0-16·6) versus not reached (NR; NR-NR; 0·13 [0·03-0·58], log-rank p=0·0016). The median time to imatinib resistance after 1 year of imatinib was 28·7 months (95% CI 18·1-39·1) versus 90·6 months (25·3-156·1; HR 0·93 [95% CI 0·51-1·71], log-rank p=0·82), after 3 years was 66·2 months (43·0-89·6) versus 127·3 months (15·0-239·7; 0·35 [0·17-0·72, log-rank p=0·0028), and after 5 years was 58·6 months (0·0-167·4) versus NR (NR-NR; 0·24 [0·05-1·12], log-rank p=0·049). Median overall survival after 1 year of imatinib was 56·0 months (95% CI 30·3-82·9) versus 105·0 months (20·6-189·6; HR 0·84 [95% CI 0·46-1·54], log-rank p=0·57), after 3 years was 104·0 months (90·7-118·7) versus 134·0 months (89·7-178·3; 0·40 [0·20-0·82], log-rank p=0·0096), and after 5 years was NR (NR-NR) versus 110·4 months (82·7-154·1; 1·28 [0·41-3·99]; log-rank p=0·67), INTERPRETATION: Imatinib interruption in patients with GIST without progressive disease is not recommended. Imatinib interruption in non-progressing patients with GIST was associated with rapid progression, faster resistance to imatinib, and shorter overall survival in the long-term follow-up when compared with imatinib continuation in patients after 3 years and 5 years of imatinib., Funding: Centre Léon Bérard, INCa, CONTICANET, Ligue Contre le Cancer, and Novartis., Competing Interests: Declaration of interests J-YB reports grants from NETSARC+, INTERSARC+, and LYRICAN+ from INCA (to the institution), DEpGyn RHU and LYRICAN+ from the Agence Nationale de la Recherche (to the institution), and ERN EURACAN from the EU commission (to the institution); research support from Novartis, Deciphera, and Bayer (to the institution); membership of steering committees for the Intrigue and Motion studies for Deciphera; and membership of the supervisory boards of Transgène and Innate Pharma. IR-C reports research grants from Bristol Myers Squibb (BMS); consulting fees from and participation on data safety boards of Adaptimmune, Agenus, Amgen, AstraZeneca, BMS, Clovis, Daiichi Sankyo, Deciphera, Eisai, EQRX, GSK, MacroGenics, Merck Serono, Mersana, MSD, Novartis, Onxeo, Roche, and Sutro Biopharma. NP reports research grants from Bayer. DP reports travel grants from Roche and Novartis. ALC reports honoraria from Deciphera and Pharmamar. All other authors declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
21. MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.
- Author
-
Pluchino M, Testi I, Minari R, Dodi A, Airò G, Mazzaschi G, Verzè M, Adorni A, Gnetti L, Azzoni C, Lagrasta CAM, Pecci F, and Tiseo M
- Subjects
- Humans, Male, Aged, Pyridones administration & dosage, Pyrimidinones administration & dosage, Oximes administration & dosage, Proto-Oncogene Proteins B-raf genetics, Imidazoles administration & dosage, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met genetics, Mutation, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
The combination of BRAF and MEK inhibitors demonstrated significant clinical benefit in patients with BRAF-mutant non-small cell lung cancer (NSCLC). However, the molecular mechanisms of acquired resistance to BRAF and MEK inhibition in NSCLC are still unknown. Herein, we report a case of a 76-year-old man with a history of smoking who was diagnosed with BRAF V600E-mutant lung adenocarcinoma (PD-L1 > 50%) and subsequently candidate to first-line therapy with pembrolizumab. After 18 months since the start of immunotherapy, computed tomography scan showed disease progression and a second-line therapy with dabrafenib and trametinib was initiated. Seven months later, due to a suspect disease progression, a left supraclavicular lymphadenectomy was performed and next-generation sequencing analysis revealed the appearance of MET exon 14 skipping mutation, while fluorescence in situ hybridization analysis showed MET amplification. The patient is still on BRAF and MEK inhibitor treatment. Our case highlights the relevance of performing tumor tissue rebiopsy at the time of progression during treatment with BRAF/MEK inhibition with the aim of identifying putative mechanisms of resistance., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
22. Intersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance.
- Author
-
Hariri A, Mirian M, Khosravi A, Zarepour A, Iravani S, and Zarrabi A
- Subjects
- Humans, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Animals, Biomarkers, Tumor metabolism, M Cells, Neoplastic Cells, Circulating drug effects, Neoplastic Cells, Circulating pathology, Neoplastic Cells, Circulating metabolism, Epithelial-Mesenchymal Transition drug effects, Drug Resistance, Neoplasm, Tumor Microenvironment drug effects, Neoplasm Metastasis, Neoplasms drug therapy, Neoplasms pathology
- Abstract
Cancer metastasis and therapy resistance are intricately linked with the dynamics of Epithelial-Mesenchymal Transition (EMT) and Circulating Tumor Cells (CTCs). EMT hybrid cells, characterized by a blend of epithelial and mesenchymal traits, have emerged as pivotal in metastasis and demonstrate remarkable plasticity, enabling transitions across cellular states crucial for intravasation, survival in circulation, and extravasation at distal sites. Concurrently, CTCs, which are detached from primary tumors and travel through the bloodstream, are crucial as potential biomarkers for cancer prognosis and therapeutic response. There is a significant interplay between EMT hybrid cells and CTCs, revealing a complex, bidirectional relationship that significantly influences metastatic progression and has a critical role in cancer drug resistance. This resistance is further influenced by the tumor microenvironment, with factors such as tumor-associated macrophages, cancer-associated fibroblasts, and hypoxic conditions driving EMT and contributing to therapeutic resistance. It is important to understand the molecular mechanisms of EMT, characteristics of EMT hybrid cells and CTCs, and their roles in both metastasis and drug resistance. This comprehensive understanding sheds light on the complexities of cancer metastasis and opens avenues for novel diagnostic approaches and targeted therapies and has significant advancements in combating cancer metastasis and overcoming drug resistance., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph + leukemias?
- Author
-
Cruz-Rodriguez N, Tang H, Bateman B, Tang W, and Deininger M
- Subjects
- Humans, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-abl metabolism, Animals, Proteolysis Targeting Chimera, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive metabolism, Fusion Proteins, bcr-abl antagonists & inhibitors, Fusion Proteins, bcr-abl metabolism, Proteolysis, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors pharmacology
- Abstract
BCR::ABL1 tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a lethal condition into a chronic ailment. With optimal management, the survival of CML patients diagnosed in the chronic phase is approaching that of age-matched controls. However, only one-third of patients can discontinue TKIs and enter a state of functional cure termed treatment-free remission (TFR), while the remainder require life-long TKI therapy to avoid the recurrence of active leukemia. Approximately 10% of patients exhibit primary or acquired TKI resistance and eventually progress to the blast phase. It is thought that recurrence after attempted TFR originates from CML stem cells (LSCs) surviving despite continued suppression of BCR::ABL1 kinase. Although kinase activity is indispensable for induction of overt CML, kinase-independent scaffold functions of BCR::ABL1 are known to contribute to leukemogenesis, raising the intriguing but as yet hypothetical possibility, that degradation of BCR::ABL1 protein may accomplish what TKIs fail to achieve - eliminate residual LSCs to turn functional into real cures. The advent of BCR::ABL1 proteolysis targeting chimeras (PROTACs), heterobifunctional molecules linking a TKI-based warhead to an E3 ligase recruiter, has moved clinical protein degradation into the realm of the possible. Here we examine the molecular rationale as well as pros and cons of degrading BCR::ABL1 protein. We review reported BCR::ABL1 PROTACs, point out limitations of available data and compounds and suggest directions for future research. Ultimately, clinical testing of a potent and specific BCR::ABL1 degrader will be required to determine the efficacy and tolerability of this approach., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
24. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance.
- Author
-
Chen Y, Lu A, Hu Z, Li J, and Lu J
- Subjects
- Humans, Molecular Targeted Therapy methods, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Animals, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors pharmacology, Receptor, ErbB-3 metabolism, Receptor, ErbB-3 antagonists & inhibitors, Receptor, ErbB-3 genetics, Drug Resistance, Neoplasm, Neoplasms drug therapy, Neoplasms genetics, Neoplasms metabolism, Neoplasms pathology, Signal Transduction drug effects
- Abstract
Human epidermal growth factor receptor-3 (ERBB3) is a member of the ERBB receptor tyrosine kinases (RTKs) and is expressed in many malignancies. Along with other ERBB receptors, ERBB3 is associated with regulating normal cell proliferation, apoptosis, differentiation, and survival, and has received increased research attention for its involvement in cancer therapies. ERBB3 expression or co-expression levels have been investigated as predictive factors for cancer prognosis and drug sensitivity. Additionally, the association between the elevated expression of ERBB3 and treatment failure in cancer therapy further established ERBB3-targeting therapy as a crucial therapeutic approach. This review delves into the molecular mechanisms of ERBB3-driven resistance to targeted therapeutics against ERBB2 and EGFR and other signal transduction inhibitors, endocrine therapy, chemotherapy, and radiotherapy. Using preclinical and clinical evidence, we synthesise and explicate how various aspects of aberrant ERBB3 activities-such as compensatory activation, signal crosstalk interactions, dysregulation in the endocytic pathway, mutations, ligand-independent activation, intrinsic kinase activity, and homodimerisation-can lead to resistance development and/or treatment failures. Several ERBB3-directed monoclonal antibodies, bispecific antibodies, and the emerging antibody-drug conjugate demonstrate encouraging clinical outcomes for improving therapeutic efficacy and overcoming resistance, especially when combined with other anti-cancer approaches. More research efforts are needed to identify appropriate biomarkers tailored for ERBB3-targeted therapies., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. DPP9 regulates NQO1 and ROS to promote resistance to chemotherapy in liver cancer cells.
- Author
-
Zhou Y, Chen Y, Xuan C, Li X, Tan Y, Yang M, Cao M, Chen C, Huang X, and Hu R
- Subjects
- Humans, Cell Line, Tumor, Kelch-Like ECH-Associated Protein 1 metabolism, Kelch-Like ECH-Associated Protein 1 genetics, Antineoplastic Agents pharmacology, Signal Transduction drug effects, NAD(P)H Dehydrogenase (Quinone) metabolism, NAD(P)H Dehydrogenase (Quinone) genetics, Reactive Oxygen Species metabolism, Drug Resistance, Neoplasm, Liver Neoplasms drug therapy, Liver Neoplasms metabolism, Liver Neoplasms genetics, Liver Neoplasms pathology, NF-E2-Related Factor 2 metabolism, NF-E2-Related Factor 2 genetics, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases metabolism, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases genetics, Gene Expression Regulation, Neoplastic drug effects
- Abstract
Chemotherapy has been the standard treatment for liver cancer. However, intrinsic or acquired drug resistance remains a major barrier to successful treatment. At present, the underlying molecular mechanisms of chemoresistance in liver cancer have not been elucidated. Dipeptidyl peptidase 9 (DPP9) is a member of the dipeptidyl peptidase IV family that has been found to be highly expressed in a variety of tumors, including liver cancer. It is unclear whether DPP9 affects chemoresistance in liver cancer. In this study, we find that DPP9 weakens the responses of liver cancer cells to chemotherapy drugs by up-regulating NQO1 and inhibiting intracellular ROS levels. In terms of mechanism, DPP9 inhibits ubiquitin-mediated degradation of NRF2 protein by binding to KEAP1, up-regulates NRF2 protein levels, promotes mRNA transcription of NQO1, and inhibits intracellular ROS levels. In addition, the NQO1 inhibitor dicoumarol can enhance the efficacy of chemotherapy drugs in liver cancer cells. Collectively, our findings suggest that inhibiting DPP9/NQO1 signaling can serve as a potential therapeutic strategy for liver cancer., Competing Interests: Declaration of competing interest The authors declare no potential conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Targeted therapies in advanced biliary malignancies: a clinical review.
- Author
-
Grewal US, Gaddam SJ, Beg MS, and Brown TJ
- Subjects
- Humans, Drug Resistance, Neoplasm, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Survival Rate, Disease Progression, Animals, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology, Biliary Tract Neoplasms genetics, Molecular Targeted Therapy, Precision Medicine, Mutation, Antineoplastic Agents pharmacology, Antineoplastic Agents administration & dosage
- Abstract
Introduction: Despite several therapeutic advancements, the proportion of patients with advanced biliary tract cancers (BTC) surviving 5 years from diagnosis remains dismal. The increasing recognition of targetable genetic alterations in BTCs has ushered in a new era in the treatment of these patients. Newer therapeutic agents targeting mutations such as isocitrate dehydrogenase (IDH), fibroblastic growth factor receptor (FGFR), human epidermal growth factor receptor (HER), and so on have established a new standard of care for treatment upon progression on frontline therapy in patients with disease harboring these mutations., Areas Covered: The current review aims to concisely summarize progress with various targeted therapy options for BTC. We also briefly discuss future directions in clinical and translational research for the adoption of a personalized approach for the treatment of unresectable or advanced BTC., Expert Opinion: Several new agents continue to emerge as feasible treatment options for patients with advanced BTC harboring targetable mutations. There is a growing need to identify mechanisms to conquer primary and acquired resistance to these agents. The identification of potential biomarkers that predict response to targeted therapy may be helpful in adopting a more tailored approach. All patients receiving treatment for advanced BTC should undergo tissue genomic profiling at diagnosis.
- Published
- 2024
- Full Text
- View/download PDF
27. Advances in the treatment of human epidermal growth factor receptor 2-positive gastric cancer.
- Author
-
Kudo T
- Subjects
- Humans, Immunoconjugates therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Protein Kinase Inhibitors therapeutic use, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized therapeutic use, Camptothecin analogs & derivatives, Stomach Neoplasms drug therapy, Receptor, ErbB-2 antagonists & inhibitors, Receptor, ErbB-2 metabolism, Trastuzumab therapeutic use
- Abstract
Human epidermal growth factor receptor 2 has been a pivotal biomarker for gastric cancer treatment strategies for many years. However, more than a decade after the ToGA trial demonstrated the efficacy of trastuzumab in improving survival, the development of treatments targeting human epidermal growth factor receptor 2 remains challenging. Several large-scale clinical trials of tyrosine kinase inhibitors, non-trastuzumab anti-human epidermal growth factor receptor 2 antibodies, and antibody-drug conjugates have failed to meet the primary endpoints. The concept of trastuzumab beyond progression and the complexity of resistance mechanisms to anti-human epidermal growth factor receptor 2 therapy after trastuzumab treatment presented significant obstacles, leading to trastuzumab being the sole therapy for human epidermal growth factor receptor 2-positive gastric cancer for some time. Nevertheless, the landscape has shifted in recent years, especially since the introduction of the antibody-drug conjugate trastuzumab deruxtecan in 2020. This has rekindled the interest in developing treatments targeting human epidermal growth factor receptor 2 in gastric cancer., (© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
28. Enhancement of chemoresistance by claudin-1-mediated formation of amino acid barriers in human lung adenocarcinoma A549 cells.
- Author
-
Kimura R, Hashimoto S, Eguchi H, Morikawa Y, Suenami K, Yoshino Y, Matsunaga T, Endo S, and Ikari A
- Subjects
- Humans, A549 Cells, Amino Acids metabolism, Reactive Oxygen Species metabolism, Large Neutral Amino Acid-Transporter 1 metabolism, Large Neutral Amino Acid-Transporter 1 genetics, NF-E2-Related Factor 2 metabolism, NF-E2-Related Factor 2 genetics, Spheroids, Cellular metabolism, Spheroids, Cellular drug effects, Gene Silencing, Drug Resistance, Neoplasm, Claudin-1 metabolism, Claudin-1 genetics, Adenocarcinoma of Lung metabolism, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung pathology, Lung Neoplasms metabolism, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms drug therapy
- Abstract
Claudin-1 (CLDN1) is highly expressed in human lung adenocarcinoma-derived A549 cells and is involved in the augmentation of chemoresistance. However, the mechanism of chemoresistance is not fully understood. In the tumor microenvironment, cancer cells are exposed to stress conditions such as hypoxia and malnutrition. Here, we investigated the effect of CLDN1 expression on amino acid (AA) flux and chemoresistance using A549 cells. The expression of L-type AA transporters, LAT1 and LAT3, was decreased by CLDN1 silencing in A549 spheroids. A reduction in extracellular AA concentration increased the expression of these AA transporters in two-dimensional (2D) cultured cells. The paracellular AA flux except for Ser, Thr, Tyr, Ala, and Gly was enhanced by CLDN1 silencing. These results suggest that CLDN1 forms a paracellular barrier to some AAs, leading to the elevation of LAT1/3 expression in spheroids. The production of reactive oxygen species in the mitochondria and cytosol was decreased by CLDN1 silencing in spheroids, resulting in downregulation of the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and its target antioxidant genes. CLDN1 silencing enhanced the cytotoxicity of anticancer drugs including doxorubicin and cisplatin, which was blocked by sulforaphane, an inducer of Nrf2 signaling. Similarly, the anticancer-induced toxicity was enhanced by Nrf2 silencing. In 2D cultured cells, the anticancer-induced toxicity was attenuated by AA deficiency and sulforaphane. We suggest that CLDN1 forms an AA barrier in spheroids, leading to the augmentation of Nrf2-dependent chemoresistance in A549 cells., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance.
- Author
-
Wellhausen N, Baek J, Gill SI, and June CH
- Subjects
- Humans, Animals, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell genetics, Hematopoietic Stem Cells immunology, Immunotherapy methods, Neoplasms therapy, Neoplasms immunology, Neoplasms genetics, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen genetics, Drug Resistance, Neoplasm
- Abstract
Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as a promising approach for achieving long-term remissions in patients with cancer. To be effective, the engineered cells must persist at therapeutically relevant levels while avoiding off-tumour toxicities, which has been challenging to realize outside of B cell and plasma cell malignancies. This Review discusses concepts to enhance the efficacy, safety and accessibility of cellular immunotherapies by endowing cells with selective resistance to small-molecule drugs or antibody-based therapies to facilitate combination therapies with substances that would otherwise interfere with the functionality of the effector cells. We further explore the utility of engineering healthy haematopoietic stem cells to confer resistance to antigen-directed immunotherapies and small-molecule targeted therapies to expand the therapeutic index of said targeted anticancer agents as well as to facilitate in vivo selection of gene-edited haematopoietic stem cells for non-malignant applications. Lastly, we discuss approaches to evade immune rejection, which may be required in the setting of allogeneic cell therapies. Increasing confidence in the tools and outcomes of genetically modified cell therapy now paves the way for rational combinations that will open new therapeutic horizons., (© 2024. Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
30. Pre-empting drug resistance.
- Author
-
Dart A
- Subjects
- Humans, Neoplasms drug therapy, Neoplasms pathology, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm
- Published
- 2024
- Full Text
- View/download PDF
31. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies.
- Author
-
van de Donk NWCJ, Chari A, and Mateos MV
- Subjects
- Humans, Drug Resistance, Neoplasm, Multiple Myeloma immunology, Multiple Myeloma therapy, Multiple Myeloma drug therapy, Antibodies, Bispecific therapeutic use, Antibodies, Bispecific immunology, Antibodies, Bispecific pharmacology, T-Lymphocytes immunology
- Abstract
Off-the-shelf T-cell-redirecting bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 have high activity in multiple myeloma with a manageable toxicity profile. However, not all patients respond to bispecific antibodies and patients can develop bispecific antibody resistance after an initial response. Mechanisms that contribute to bispecific antibody resistance are multifactorial and include tumour-related factors, such as high tumour burden, expression of T-cell inhibitory ligands, and antigen loss. Resistance due to antigen escape can be prevented by simultaneously targeting two tumour-associated antigens with a trispecific antibody or a combination of two bispecific antibodies. There is also increasing evidence that primary resistance to bispecific antibodies is associated with impaired baseline T-cell function. Long-term exposure to bispecific antibodies with chronic T-cell stimulation further aggravates T-cell dysfunction, which could contribute to failure of disease control. Therapeutic interference with T-cell exhaustion by targeting inhibitory or costimulatory pathways could improve bispecific antibody-mediated antitumour activity. The immunosuppressive microenvironment also contributes to bispecific antibody resistance. CD38-targeting antibodies hold promise as combination partners for bispecific antibodies because of their potential to eliminate CD38
+ immune suppressor cells. In conclusion, a better understanding of the mechanisms underlying the absence of disease response has provided novel insights to optimise T-cell activity and bispecific antibody efficacy in multiple myeloma., Competing Interests: Declaration of interests NWCJvdD has received research support, paid to his institution, from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, Cellectis, and BMS and has been on advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Kite Pharma, Merck, Pfizer, AbbVie, and Servier. AC has received research support from Janssen Pharmaceuticals; has received honoraria for lectures from Antengene; and has been a consultant or advisor for AbbVie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech–Roche, GlaxoSmithKline, Janssen Pharmaceuticals, Karyopharm Therapeutics, Millennium–Takeda, and Sanofi–Genzyme. MVM has been on advisory boards for Amgen, Bristol Myers Squibb–Celgene, GlaxoSmithKline, Janssen Cilag, Kite Pharma, Oncopeptides, Pfizer, Roche, Sanofi, and Stemline and is a speaker bureau member of Janssen Cilag., (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)- Published
- 2024
- Full Text
- View/download PDF
32. Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells.
- Author
-
Latancia MT, Leandro GDS, Bastos AU, Moreno NC, Ariwoola AA, Martins DJ, Ashton NW, Ribeiro VC, Hoch NC, Rocha CRR, Woodgate R, and Menck CFM
- Subjects
- Humans, Cell Line, Tumor, Tumor Suppressor Proteins metabolism, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins deficiency, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, DNA Damage, Cell Survival drug effects, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms metabolism, Brain Neoplasms pathology, DNA Repair, Gene Knockout Techniques, Temozolomide pharmacology, Glioblastoma genetics, Glioblastoma drug therapy, Glioblastoma metabolism, Glioblastoma pathology, DNA-Directed DNA Polymerase metabolism, DNA-Directed DNA Polymerase genetics, Drug Resistance, Neoplasm, DNA Polymerase iota, DNA Modification Methylases metabolism, DNA Modification Methylases genetics, DNA Repair Enzymes metabolism, DNA Repair Enzymes genetics
- Abstract
Glioblastoma (GBM) is a highly aggressive brain tumor associated with poor patient survival. The current standard treatment involves invasive surgery, radiotherapy, and chemotherapy employing temozolomide (TMZ). Resistance to TMZ is, however, a major challenge. Previous work from our group has identified candidate genes linked to TMZ resistance, including genes encoding translesion synthesis (TLS) DNA polymerases iota (Polɩ) and kappa (Polκ). These specialized enzymes are known for bypassing lesions and tolerating DNA damage. Here, we investigated the roles of Polɩ and Polκ in TMZ resistance, employing MGMT-deficient U251-MG glioblastoma cells, with knockout of either POLI or POLK genes encoding Polɩ and Polκ, respectively, and assess their viability and genotoxic stress responses upon subsequent TMZ treatment. Cells lacking either of these polymerases exhibited a significant decrease in viability following TMZ treatment compared to parental counterparts. The restoration of the missing polymerase led to a recovery of cell viability. Furthermore, knockout cells displayed increased cell cycle arrest, mainly in late S-phase, and lower levels of genotoxic stress after TMZ treatment, as assessed by a reduction of γH2AX foci and flow cytometry data. This implies that TMZ treatment does not trigger a significant H2AX phosphorylation response in the absence of these proteins. Interestingly, combining TMZ with Mirin (double-strand break repair pathway inhibitor) further reduced the cell viability and increased DNA damage and γH2AX positive cells in TLS KO cells, but not in parental cells. These findings underscore the crucial roles of Polɩ and Polκ in conferring TMZ resistance and the potential backup role of homologous recombination in the absence of these TLS polymerases. Targeting these TLS enzymes, along with double-strand break DNA repair inhibition, could, therefore, provide a promising strategy to enhance TMZ's effectiveness in treating GBM., Competing Interests: Declaration of Competing Interest CFMM is an Editorial Board Member of DNA Repair. RW is an Associate Editor of DNA Repair. Neither were involved in the editorial review or the decision to publish this article., (Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
33. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer.
- Author
-
Zang PD, Seylani A, Yu EY, and Dorff TB
- Subjects
- Humans, Male, Animals, Signal Transduction drug effects, Mutation, Proteolysis, Disease Progression, Receptors, Androgen metabolism, Receptors, Androgen genetics, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Prostatic Neoplasms genetics, Androgen Receptor Antagonists pharmacology, Molecular Targeted Therapy, Drug Resistance, Neoplasm
- Abstract
Introduction: The androgen receptor (AR) is a critical driver of prostate cancer progression, and the advent of androgen receptor pathway inhibitors (ARPIs) has transformed the treatment landscape of metastatic prostate cancer. However, resistance to ARPIs eventually develops via mutations in AR, AR overexpression, and alternative AR signaling which have required novel approaches to target effectively., Areas Covered: The mechanism of action and early clinical results of proteolysis targeting chimera (PROTAC) agents targeting AR are reviewed. Preclinical and early clinical data for other emerging AR-targeting therapeutics, including dual-action androgen receptor inhibitors (DAARIs) and anitens that target the N-terminal domain of AR, were also identified through literature search for agents which may circumvent resistance through AR splice variants and AR ligand-binding domain mutations. The literature search utilized PubMed to identify articles that were relevant to this review from 2000 to 2024., Expert Opinion: PROTACs, DAARIs, and anitens represent novel and promising AR-targeting therapeutics that may become an important part of prostate cancer treatment in the future. Elucidating mechanisms of resistance, including ability of these agents to target full length AR, may yield further insights into maximal therapeutic efficacy aimed at silencing AR signaling.
- Published
- 2024
- Full Text
- View/download PDF
34. A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020-present.
- Author
-
Huang X, Xu S, Duan L, Xu S, and Zhu W
- Subjects
- Humans, Animals, Patents as Topic, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Protein Kinase Inhibitors pharmacology, Neoplasms drug therapy, Neoplasms pathology, Antineoplastic Agents pharmacology, Drug Development, Drug Resistance, Neoplasm
- Abstract
Introduction: Cyclin-dependent protein kinase 4/6 (CDK4/6) is a class of serine/threonine protein kinases that plays a key role in the regulation of the cell cycle. CDK4/6 is highly expressed in cancers such as breast cancer, melanoma, and non-small cell lung cancer (NSCLC). Currently, a variety of CDK4/6 inhibitors have been developed, aiming to develop effective inhibitors to solve CDK4/6 resistance and toxicity., Areas Covered: This article searches patents through Espacenet and reviews the development of widely studied CDK inhibitors and FDA-approved CDK4/6 inhibitors, as well as the latest progress of patented inhibitors with good inhibitory activity against CDK4/6 from 2020 to now., Expert Opinion: CDK4/6 is highly expressed in many tumors and has become an important anti-tumor target. Among the patents from 2020 to the present, many inhibitors have good kinase inhibitory effects on CDK4/6 and also show great development potential in anti-tumor. However, there is still an urgent need to develop novel CDK4/6 inhibitors that address challenges such as drug resistance, toxicity, and selectivity.
- Published
- 2024
- Full Text
- View/download PDF
35. Drug resistance in human cancers - Mechanisms and implications.
- Author
-
Vijayakumar S, Dhakshanamoorthy R, Baskaran A, Sabari Krishnan B, and Maddaly R
- Subjects
- Humans, Tumor Microenvironment drug effects, Mutation, Drug Resistance, Neoplasm, Neoplasms drug therapy, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology
- Abstract
Cancers have complex etiology and pose a significant impact from the health care perspective apart from the socio-economic implications. The enormity of challenge posed by cancers can be understood from the fact that clinical trials for cancer therapy has yielded minimum potential promises compared to those obtained for other diseases. Surgery, chemotherapy and radiotherapy continue to be the mainstay therapeutic options for cancers. Among the challenges posed by these options, induced resistance to chemotherapeutic drugs is probably the most significant contributor for poor prognosis and ineffectiveness of the therapy. Drug resistance is a property exhibited by almost all cancer types including carcinomas, leukemias, myelomas, sarcomas and lymphomas. The mechanisms by which drug resistance is induced include the factors within the tumor microenvironment, mutations in the genes responsible for drug metabolism, changes in the surface drug receptors and increased drug efflux. We present here comprehensively the drug resistance in cancers along with their mechanisms. Also, apart from resistance to regularly used chemotherapeutic drugs, we present resistance induction to new generation therapeutic agents such as monoclonal antibodies. Finally, we have discussed the experimental approaches to understand the mechanisms underlying induction of drug resistance and potential ways to mitigate induced drug resistance., Competing Interests: Declaration of competing interest All authors declare that they have no conflicts of interests, financial or otherwise., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Circulating tumor cells with increasing aneuploidy predict inferior prognosis and therapeutic resistance in small cell lung cancer.
- Author
-
Xie Z, Wang Y, Chen T, Fan W, Wei L, Liu B, Situ X, Zhan Q, Fu T, Tian T, Li S, He Q, Zhou J, Wang H, Du J, Tseng HR, Lei Y, Tang KJ, and Ke Z
- Subjects
- Humans, Female, Male, Middle Aged, Prognosis, Aged, Progression-Free Survival, Adult, Neoplastic Cells, Circulating pathology, Neoplastic Cells, Circulating metabolism, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma blood, Small Cell Lung Carcinoma genetics, Small Cell Lung Carcinoma mortality, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms blood, Lung Neoplasms genetics, Lung Neoplasms mortality, Aneuploidy, Drug Resistance, Neoplasm, Biomarkers, Tumor genetics, Biomarkers, Tumor blood
- Abstract
Aims: Treatment resistance commonly emerges in small cell lung cancer (SCLC), necessitating the development of novel and effective biomarkers to dynamically assess therapeutic efficacy. This study aims to evaluate the clinical utility of aneuploid circulating tumor cells (CTCs) for risk stratification and treatment response monitoring., Methods: A total of 126 SCLC patients (two cohorts) from two independent cancer centers were recruited as the study subjects. Blood samples were collected from these patients and aneuploid CTCs were detected. Aneuploid CTC count (ACC) and aneuploid CTC score (ACS), were used to predict progression-free survival (PFS) and overall survival (OS). The performance of the ACC and the ACS was evaluated by calculating the area under the receiver operating characteristic (ROC) curve (AUC)., Results: Compared to ACC, ACS exhibited superior predictive power for PFS and OS in these 126 patients. Moreover, both univariate and multivariate analyses revealed that ACS was an independent prognostic factor. Dynamic ACS changes reflected treatment response, which is more precise than ACC changes. ACS can be used to assess chemotherapy resistance and is more sensitive than radiological examination (with a median lead time of 2.8 months; P < 0.001). When patients had high ACS levels (> 1.115) at baseline, the combination of immunotherapy and chemotherapy resulted in longer PFS (median PFS, 7.7 months; P = 0.007) and OS (median OS, 16.3 months; P = 0.033) than chemotherapy alone (median PFS, 4.9 months; median OS, 13.6 months)., Conclusions: ACS could be used as a biomarker for risk stratification, treatment response monitoring, and individualized therapeutic intervention in SCLC patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism.
- Author
-
Hsu CY, Yanagi T, Maeda T, Nishihara H, Funakoshi T, Miyamoto K, Iwamoto R, Takahashi K, and Ujiie H
- Subjects
- Animals, Humans, Mice, Female, Disease Models, Animal, Antineoplastic Agents, Immunological pharmacology, Antineoplastic Agents, Immunological therapeutic use, PTEN Phosphohydrolase genetics, PTEN Phosphohydrolase metabolism, Paget Disease, Extramammary drug therapy, Paget Disease, Extramammary genetics, Paget Disease, Extramammary pathology, Paget Disease, Extramammary metabolism, Drug Resistance, Neoplasm, Trastuzumab therapeutic use, Trastuzumab pharmacology, Xenograft Model Antitumor Assays, Receptor, ErbB-2 genetics, Receptor, ErbB-2 metabolism
- Abstract
Background/objectives: Extramammary Paget disease (EMPD) is a rare, cutaneous intraepithelial adenocarcinoma typically treated with wide local excision. Unfortunately, a number of patients with metastases show poor responses to chemotherapy. While some studies have explored trastuzumab's effectiveness against EMPD positive for human epidermal growth factor receptor 2 (HER2), trastuzumab resistance (TR) may emerge after anti-HER2 therapy., Methods/subjects: In this study, we established TR EMPD patient-derived xenografts (PDX) that replicated the histological and HER2 expression traits of naive EMPD tumours., Results: Cancer gene analyses revealed a loss of the PTEN gene in TR tumours, which was further confirmed by immunohistochemical staining and immunoblotting to test for protein expression levels. Reduced PTEN levels correlated with increased protein kinase B (Akt) phosphorylation and p27 downregulation, suggesting a potential mechanism for trastuzumab resistance in EMPD cells. In the trastuzumab-sensitive EMPD-PDX mouse model, PTEN inhibitors partially restored trastuzumab-mediated tumour regression. The TR EMPD-PDX responded favourably to targeted therapy (lapatinib, abemaciclib, palbociclib) and chemotherapy (eribulin, docetaxel, trastuzumab deruxtecan)., Conclusions: This study demonstrates an innovative TR EMPD-PDX model and introduces promising antineoplastic effects with various treatments for TR EMPD tumours., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2024
- Full Text
- View/download PDF
38. A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis.
- Author
-
Guo J, Ma X, Liu D, Wang F, Xia J, Zhang B, Zhao P, Zhong F, Chen L, Long Q, Jiang L, Zhang S, Liao N, Wang J, Wu W, Sun J, Huang M, Cheng Z, Huang G, and Zou C
- Subjects
- Humans, Cell Line, Tumor, Cell Movement drug effects, Deoxycytidine analogs & derivatives, Deoxycytidine pharmacology, Deoxycytidine therapeutic use, Gemcitabine pharmacology, Gemcitabine therapeutic use, Gene Expression Regulation, Neoplastic drug effects, Prognosis, Tumor Microenvironment drug effects, Urothelium blood supply, Urothelium drug effects, Urothelium pathology, Zinc Finger E-box-Binding Homeobox 1 genetics, Zinc Finger E-box-Binding Homeobox 1 metabolism, Collagen Type IV genetics, Collagen Type IV metabolism, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition drug effects, Integrin beta1 metabolism, Integrin beta1 genetics, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Neovascularization, Pathologic drug therapy, Neovascularization, Pathologic pathology, Neovascularization, Pathologic genetics, Urinary Bladder Neoplasms blood supply, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms pathology
- Abstract
Drug resistance and tumor recurrence remain clinical challenges in the treatment of urothelial carcinoma (UC). However, the underlying mechanism is not fully understood. Here, we performed single-cell RNA sequencing and identified a subset of urothelial cells with epithelial-mesenchymal transition (EMT) features (EMT-UC), which is significantly correlated with chemotherapy resistance and cancer recurrence. To validate the clinical significance of EMT-UC, we constructed EMT-UC like cells by introducing overexpression of two markers, Zinc Finger E-Box Binding Homeobox 1 (ZEB1) and Desmin (DES), and examined their histological distribution characteristics and malignant phenotypes. EMT-UC like cells were mainly enriched in UC tissues from patients with adverse prognosis and exhibited significantly elevated EMT, migration and gemcitabine tolerance in vitro. However, EMT-UC was not specifically identified from tumorous tissues, certain proportion of them were also identified in adjacent normal tissues. Tumorous EMT-UC highly expressed genes involved in malignant behaviors and exhibited adverse prognosis. Additionally, tumorous EMT-UC was associated with remodeled tumor microenvironment (TME), which exhibited high angiogenic and immunosuppressive potentials compared with the normal counterparts. Furthermore, a specific interaction of COL4A1 and ITGB1 was identified to be highly enriched in tumorous EMT-UC, and in the endothelial component. Targeting the interaction of COL4A1 and ITGB1 with specific antibodies significantly suppressed tumorous angiogenesis and alleviated gemcitabine resistance of UC. Overall, our findings demonstrated that the driven force of chemotherapy resistance and recurrence of UC was EMT-UC mediated COL4A1-ITGB1 interaction, providing a potential target for future UC treatment., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies.
- Author
-
Hao JL, Li XY, Liu YT, Lang JX, Liu DJ, and Zhang CD
- Subjects
- Humans, Drug Resistance, Neoplasm, Molecular Targeted Therapy methods, Antineoplastic Agents, Immunological therapeutic use, Stomach Neoplasms drug therapy, Immunoconjugates therapeutic use
- Abstract
Antibody-drug conjugates (ADCs) represent a crucial component of targeted therapies in gastric cancer, potentially altering traditional treatment paradigms. Many ADCs have entered rigorous clinical trials based on biological theories and preclinical experiments. Modality trials have also been conducted in combination with monoclonal antibody therapies, chemotherapies, immunotherapies, and other treatments to enhance the efficacy of drug coordination effects. However, ADCs exhibit limitations in treating gastric cancer, including resistance triggered by their structure or other factors. Ongoing intensive researches and preclinical experiments are yielding improvements, while enhancements in drug development processes and concomitant diagnostics during the therapeutic period actively boost ADC efficacy. The optimal treatment strategy for gastric cancer patients is continually evolving. This review summarizes the clinical progress of ADCs in treating gastric cancer, analyzes the mechanisms of ADC combination therapies, discusses resistance patterns, and offers a promising outlook for future applications in ADC drug development and companion diagnostics., (© 2024. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.)
- Published
- 2024
- Full Text
- View/download PDF
40. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
- Author
-
Muscolino P, Scimone C, Sapuppo E, Micali V, Vasta I, Santacaterina A, Santarpia M, and Russo A
- Subjects
- Humans, Antineoplastic Agents therapeutic use, ErbB Receptors genetics, ErbB Receptors antagonists & inhibitors, Indoles, Pyrimidines, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Drug Resistance, Neoplasm, Gefitinib therapeutic use, Aniline Compounds therapeutic use, Acrylamides therapeutic use, Protein Kinase Inhibitors therapeutic use
- Abstract
Competing Interests: Disclosure Dr Russo has received advisory board, consultancy or speaker bureau honoraria from AstraZeneca, MSD, Novartis, Pfizer, BMS, Roche, Takeda, and Amgen outside the submitted work; compensated activity for editorial projects from AstraZeneca, MSD, Novartis, and Roche outside the submitted work. The other authors declare no conflicts of interests.
- Published
- 2024
- Full Text
- View/download PDF
41. Cancer plasticity in therapy resistance: Mechanisms and novel strategies.
- Author
-
Niu X, Liu W, Zhang Y, Liu J, Zhang J, Li B, Qiu Y, Zhao P, Wang Z, and Wang Z
- Subjects
- Humans, Animals, Epigenesis, Genetic, Neoplasms drug therapy, Neoplasms therapy, Neoplasms pathology, Neoplasms genetics, Drug Resistance, Neoplasm, Tumor Microenvironment drug effects, Cell Plasticity drug effects, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology
- Abstract
Therapy resistance poses a significant obstacle to effective cancer treatment. Recent insights into cell plasticity as a new paradigm for understanding resistance to treatment: as cancer progresses, cancer cells experience phenotypic and molecular alterations, corporately known as cell plasticity. These alterations are caused by microenvironment factors, stochastic genetic and epigenetic changes, and/or selective pressure engendered by treatment, resulting in tumor heterogeneity and therapy resistance. Increasing evidence suggests that cancer cells display remarkable intrinsic plasticity and reversibly adapt to dynamic microenvironment conditions. Dynamic interactions between cell states and with the surrounding microenvironment form a flexible tumor ecosystem, which is able to quickly adapt to external pressure, especially treatment. Here, this review delineates the formation of cancer cell plasticity (CCP) as well as its manipulation of cancer escape from treatment. Furthermore, the intrinsic and extrinsic mechanisms driving CCP that promote the development of therapy resistance is summarized. Novel treatment strategies, e.g., inhibiting or reversing CCP is also proposed. Moreover, the review discusses the multiple lines of ongoing clinical trials globally aimed at ameliorating therapy resistance. Such advances provide directions for the development of new treatment modalities and combination therapies against CCP in the context of therapy resistance., Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
42. KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression.
- Author
-
Zhang H, Zheng Y, Wang Z, Dong L, Xue L, Tian X, Deng H, Xue Q, Gao S, Gao Y, Li C, and He J
- Subjects
- Humans, Cell Line, Tumor, Animals, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Neoplasm Metastasis, Ubiquitin-Protein Ligases metabolism, Ubiquitin-Protein Ligases genetics, Ubiquitination drug effects, Mice, Cell Proliferation drug effects, Tripartite Motif Proteins, DNA-Binding Proteins, Nuclear Proteins, Cisplatin pharmacology, Drug Resistance, Neoplasm, Esophageal Squamous Cell Carcinoma drug therapy, Esophageal Squamous Cell Carcinoma genetics, Esophageal Squamous Cell Carcinoma pathology, Esophageal Squamous Cell Carcinoma metabolism, Kruppel-Like Transcription Factors metabolism, Kruppel-Like Transcription Factors genetics, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Esophageal Neoplasms metabolism, Esophageal Neoplasms genetics, Neural Cell Adhesion Molecule L1 metabolism, Neural Cell Adhesion Molecule L1 genetics, Gene Expression Regulation, Neoplastic
- Abstract
Krüppel-like factor 12 (KLF12) has been characterized as a transcriptional repressor, and previous studies have unveiled its roles in angiogenesis, neural tube defect, and natural killer (NK) cell proliferation. However, the contribution of KLF12 to cancer treatment remains undefined. Here, we show that KLF12 is downregulated in various cancer types, and KLF12 downregulation promotes cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma (ESCC). Mechanistically, KLF12 binds to the promoters of L1 Cell Adhesion Molecule (L1CAM) and represses its expression. Depletion of L1CAM abrogates cisplatin resistance and cancer metastasis caused by KLF12 loss. Moreover, the E3 ubiquitin ligase tripartite motif-containing 27 (TRIM27) binds to the N-terminal region of KLF12 and ubiquitinates KLF12 at K326 via K33-linked polyubiquitination. Notably, TRIM27 depletion enhances the transcriptional activity of KLF12 and consequently inhibits L1CAM expression. Overall, our study elucidated a novel regulatory mechanism involving TRIM27, KLF12 and L1CAM, which plays a substantial role in cisplatin resistance and cancer metastasis in ESCC. Targeting these genes could be a promising approach for ESCC treatment., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
- Author
-
Decaux O, Fontan J, Perrot A, Karlin L, Touzeau C, Schulmann S, Manier S, Belhadj K, Trebouet A, Zunic P, Schiano De Colella JM, Castel B, Van De Wyngaert Z, Pica GM, Tiab M, Kuhnowski F, Bouketouche M, Rigaudeau S, Benramdane R, Tekle C, Lafore R, Gaucher M, Corre J, and Leleu X
- Subjects
- Humans, Retrospective Studies, Male, Female, Aged, Middle Aged, Treatment Outcome, Drug Resistance, Neoplasm, Adult, Aged, 80 and over, Recurrence, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Multiple Myeloma diagnosis, Dexamethasone administration & dosage, Dexamethasone therapeutic use, Dexamethasone adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Thalidomide analogs & derivatives, Thalidomide administration & dosage, Thalidomide therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects
- Abstract
Background: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd)., Methods: Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression-free survival (PFS) and response rates. Verbatim terms for adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities and not graded for severity., Results: A total of 294 and 299 patients were included in the effectiveness and safety populations, respectively. IMAGE included patients who received one prior line of treatment (10.2%) and were daratumumab-refractory (19.1%). At median follow-up of 14.2 months, median PFS in the effectiveness population was 12.4 months (95% CI 9.0-15.0). Overall response and very good partial response rates were 46.3% and 27.9%, respectively. Subgroup analyses reflected similar results. In the safety population, 26.4% of patients reported at least one AE; the most common any-grade AE was neutropenia (9.4%)., Conclusion: IMAGE demonstrated Isa-Pd had meaningful effectiveness in median PFS and depth of response and no new safety signals in a real-world context, consistent with clinical trial results., (© 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
44. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.
- Author
-
Tanabe K, Kobayashi S, Maezawa Y, Ishihara K, Inoue N, Izumi K, Fujiwara M, Toide M, Yamamoto T, Uehara S, Araki S, Inoue M, Takazawa R, Numao N, Ohtsuka Y, Tanaka H, Yoshida S, and Fujii Y
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, Prognosis, Aged, 80 and over, Drug Resistance, Neoplasm, Adult, Biomarkers, Tumor, Antineoplastic Agents, Immunological therapeutic use, Progression-Free Survival, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell secondary, Carcinoma, Transitional Cell mortality, Urologic Neoplasms drug therapy, Urologic Neoplasms pathology, Urologic Neoplasms mortality, Urologic Neoplasms immunology, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology, Urinary Bladder Neoplasms mortality, Neutrophils, Antibodies, Monoclonal, Humanized therapeutic use
- Abstract
Background: This study aimed to investigate the prognostic value of the Gustave Roussy Immune score (GRIm-score) in platinum-refractory metastatic urothelial carcinoma (UC) treated with pembrolizumab., Methods: This multicenter retrospective study (YUSHIMA study) evaluated 331 patients with metastatic UC treated with pembrolizumab after platinum-based chemotherapy between January 2018 and June 2023 at 13 institutions. We collected pretreatment variables, including the GRIm-score based on serum albumin, lactate dehydrogenase, and neutrophil-to-lymphocyte ratio. The patients were divided into low and high GRIm-score groups. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were determined using the multivariate Cox proportional hazard model., Results: During the median follow-up period of 7.3 months, 278 (84%) patients showed disease progression, and 223 (67%) died from any cause. Multivariate analysis revealed that the high GRIm-score group was an independent and significant adverse prognostic factor of both OS and PFS (hazard ratio, 1.65 and 1.82, respectively; both p < 0.001) along with Eastern Cooperative Oncology Group Performance Status of ≥ 2 (both p < 0.001), presence of visceral metastasis (both p < 0.001), and hemoglobin of < 9.2 g/dL (p = 0.030 and p = 0.038). C-reactive protein of > 42 mg/L was a significant prognostic factor for OS (p = 0.001)., Conclusion: The GRIm-score is an independent prognostic marker for survival outcomes in patients with platinum-refractory metastatic UC treated with pembrolizumab., (© 2024. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
45. A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokineinduced killer cells: a first-in-human case report.
- Author
-
Elice F, Sommaggio R, Cappuzzello E, Riva M, Tisi MC, Bernardi M, Bozza A, Catanzaro D, Chieregato K, Merlo A, Giaretta I, Pieta AD, Krampera M, Visco C, Trentin L, Visentin A, Tosetto A, Astori G, and Rosato A
- Subjects
- Humans, Male, Killer Cells, Natural immunology, Killer Cells, Natural drug effects, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological administration & dosage, Middle Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse therapy, Lymphoma, Large B-Cell, Diffuse pathology
- Published
- 2024
- Full Text
- View/download PDF
46. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice.
- Author
-
Du WY, Masuda H, Nagaoka K, Yasuda T, Kuge K, Seto Y, Kakimi K, and Nomura S
- Subjects
- Animals, Mice, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes drug effects, CTLA-4 Antigen antagonists & inhibitors, Humans, Female, Programmed Cell Death 1 Receptor antagonists & inhibitors, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Stomach Neoplasms immunology, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Mice, Inbred C57BL, Peritoneal Neoplasms secondary, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms immunology, Drug Resistance, Neoplasm, Janus Kinase Inhibitors pharmacology, Janus Kinase Inhibitors therapeutic use, Tumor Microenvironment drug effects
- Abstract
Background: Cancer immunotherapy aims to unleash the immune system's potential against cancer cells, providing sustained relief for tumors responsive to immune checkpoint inhibitors (ICIs). While promising in gastric cancer (GC) trials, the efficacy of ICIs diminishes in the context of peritoneal dissemination. Our objective is to identify strategies to enhance the impact of ICI treatment specifically for cases involving peritoneal dissemination in GC., Methods: The therapeutic efficacy of anti-PD1, CTLA4 treatment alone, or in combination was assessed using the YTN16 peritoneal dissemination tumor model. Peritoneum and peritoneal exudate cells were collected for subsequent analysis. Immunohistochemical staining, flow cytometry, and bulk RNA-sequence analyses were conducted to evaluate the tumor microenvironment (TME). A Janus kinase inhibitor (JAKi) was introduced based on the pathway analysis results., Results: Anti-PD1 and anti-CTLA4 combination treatment (dual ICI treatment) demonstrated therapeutic efficacy in certain mice, primarily mediated by CD8 + T cells. However, in mice resistant to dual ICI treatment, even with CD8 + T cell infiltration, most of the T cells exhibited an exhaustion phenotype. Notably, resistant tumors displayed abnormal activation of the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway compared to the untreated group, with observed infiltration of macrophages, neutrophils, and Tregs in the TME. The concurrent administration of JAKi rescued CD8 + T cells function and reshaped the immunosuppressive TME, resulting in enhanced efficacy of the dual ICI treatment., Conclusion: Dual ICI treatment exerts its anti-tumor effects by increasing tumor-specific CD8 + T cell infiltration, and the addition of JAKi further improves ICI resistance by reshaping the immunosuppressive TME., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
47. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
- Author
-
Roussel M, Texier N, Nael V, Bitetti J, Paka P, Kerbouche N, Sail L, Colin X, and Leleu X
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Treatment Outcome, Retrospective Studies, Adult, Aged, 80 and over, Drug Resistance, Neoplasm, Recurrence, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Multiple Myeloma diagnosis, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized administration & dosage
- Abstract
Objectives: The aim of this noninterventional, retrospective ALFA study was to describe belantamab mafodotin effectiveness and safety in patients with relapsed/refractory multiple myeloma in a real-world setting in France., Methods: Response rate, progression-free survival (PFS), overall survival (OS), and safety were assessed., Results: Among the 184 patients initiating belantamab mafodotin treatment, the overall response rate was 32.7% (≥very good partial response [VGPR] 20.4%, partial response [PR] 12.3%). The median PFS (mPFS) was 2.4 months (95% confidence interval [CI]: 1.9, 3.3), and median OS (mOS) was 8.8 months (95% CI: 6.3, 11.6). According to best response, mPFS was 20.6 months (95% CI: 12.1, not reached [NR]) in patients with ≥VGPR and 7.1 months (95% CI: 4.6, 9.4) in patients with PR; mOS was NR in patients with ≥VGPR and 17.5 months (95% CI: 7.7, NR) in patients with PR. For both OS and PFS, no differences were found in subgroups of interest. The adverse events (AEs) reported in 159 patients (86.4%) were mostly ocular AEs., Conclusions: ALFA, the largest real-world cohort conducted so far, confirms the results of belantamab mafodotin as reported in the DREAMM-2 clinical trial. The clinical benefit is significant as long as the patient is a responder., (© 2024 GSK and The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
48. KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2.
- Author
-
Li Z, Lu X, Zhang J, Liu T, Xu M, Liu S, and Liang J
- Subjects
- Humans, Acetylation, Animals, Mice, Apoptosis drug effects, Glycolysis drug effects, Cell Line, Tumor, A549 Cells, Mice, Nude, Cell Proliferation drug effects, Xenograft Model Antitumor Assays, Cell Survival drug effects, Mice, Inbred BALB C, Cisplatin pharmacology, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms metabolism, Lung Neoplasms genetics, Thyroid Hormone-Binding Proteins, Drug Resistance, Neoplasm, Thyroid Hormones metabolism, Carrier Proteins metabolism, Carrier Proteins genetics, Membrane Proteins metabolism, Membrane Proteins genetics, Antineoplastic Agents pharmacology
- Abstract
Cisplatin (CDDP)-based chemotherapy resistance is a major challenge for lung cancer treatment. PKM2 is the rate-limiting enzyme of glycolysis, which is associated with CDDP resistance. KAT8 is an acetyltransferase that regulates lung cancer progression. Thus, we aimed to explore whether KAT8 regulates PKM2 acetylation to participate in CDDP resistance. CDDP resistance was analyzed by CCK-8, flow cytometry and western blotting. To explore the regulation of KAT8 on PKM2, coimmunoprecipitation (Co-IP), immunofluorescence and immunoprecipitation followed by western blotting were performed. Glycolysis was determined using glucose consumption, lactate production, ATP level detection kits and extracellular acidification rate assay. We observed that KAT8 levels were downregulated in CDDP-treated A549 and PC9 cells. Interference with KAT8 inhibited cell viability, promoted apoptosis and upregulated PARP1 and cleaved-PARP1 levels of A549 cells treated with CDDP, suggesting the sensitivity to CDDP was enhanced, while KAT8 overexpression attenuated the CDDP sensitivity. Moreover, KAT8 interacted with PKM2 to promote the PKM2 K433 acetylation. PKM2 K433 mutated plasmids inhibited the si-KAT8-regulated cell viability, apoptosis and glycolysis compared with PKM2-WT. Besides, KAT8 reversed the inhibition of tumor growth caused by CDDP. In conclusion, KAT8-mediated PKM2 K433 acetylation was associated with the resistance of lung cancer cells to CDDP. The findings may provide a new idea for the treatment of CDDP-resistant lung cancer., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
49. Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report.
- Author
-
Cai F, Zhao Y, Song S, Zhao D, Zheng Z, and Xu L
- Subjects
- Humans, Female, Antineoplastic Agents therapeutic use, Protein Kinase Inhibitors therapeutic use, Middle Aged, Indoles, Pyrimidines, Aniline Compounds therapeutic use, Acrylamides therapeutic use, ErbB Receptors genetics, Drug Resistance, Neoplasm, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Crown Ethers therapeutic use, Adenocarcinoma of Lung drug therapy, Adenocarcinoma of Lung genetics, Quinazolines therapeutic use, Mutation
- Abstract
Based on the FLAURA and AURA III trials, compared to first- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), osimertinib provides a longer overall survival benefit for patients with untreated EGFR mutated non-small cell lung cancer. Similar to other EGFR-TKIs, drug resistance is, however, inevitable. The most common mechanism of acquired resistance to first-line osimertinib therapy is the C797S mutation, which accounts for 6% of cases. In view of the current challenges of the development of the next generation of EGFR inhibitors, the mechanism of third-generation targeted drug resistances and targeted strategies are key for further exploration. Our case report discusses a female patient with advanced lung adenocarcinoma carrying the EGFR exon19 E746_A750delinsIP mutation who received osimertinib as first-line therapy and acquired C797S resistance during treatment. The patient was then treated with icotinib for 8 months until the disease progressed. Icotinib may be effective in patients with the EGFR 19del-C797S resistant mutation acquired after osimertinib treatment., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
50. Time-dependent cost comparison and health economic impact analysis of second-line interventions for transplant-ineligible patients with relapsed or refractory diffuse large B cell lymphoma.
- Author
-
Kurte MS, Siefen AC, Jakobs F, Poos T, von Tresckow J, von Tresckow B, Reinhardt HC, and Kron F
- Subjects
- Humans, Models, Economic, Health Care Costs, Drug Resistance, Neoplasm, Recurrence, Treatment Outcome, Lymphoma, Large B-Cell, Diffuse economics, Lymphoma, Large B-Cell, Diffuse therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Lymphoma, Large B-Cell, Diffuse mortality, Cost-Benefit Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols economics
- Abstract
Objectives: Novel interventions (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tafasitamab-lenalidomide [Tafa-L], polatuzumab-rituximab-bendamustine [pola-BR]) improve clinical outcomes in second-line (2 L) treatment of transplant-ineligible patients with early relapse or refractory (R/R) diffuse large B cell lymphoma (DLBCL). The costs vary depending on the respective treatment regimen and the treatment duration, difficult comparability in reimbursement decisions. The objective was to analyze the health economic impacts of novel 2 L interventions and conventional immunochemotherapies (bendamustine-rituximab [BR], rituximab-gemcitabine-oxaliplatin [R-GemOx]) from a German healthcare payer's perspective as a function of treatment duration., Methods: An economic model was developed to compare treatment costs of 2 L interventions depending on the treatment duration. Treatment duration was measured by progression-free survival (PFS), identified based on a systematic review. Total and average costs were calculated over 5 years to evaluate incremental costs at median PFS for each intervention., Results: Average costs per month at median PFS ranged from €2846 (95% CI: 5067-1641) to €40 535 (95% CI: 91180-N/A) for BR and liso-cel, respectively. Incremental costs at the lowest median PFS (R-GemOx: 5.3 months) revealed -€664, €5560, €11 817, €53 145, and €67 745 for BR, Tafa-L, pola-BR, axi-cel, and liso-cel as compared to R-GemOx, respectively., Conclusions: Analyses uncovered a variation of incremental costs of 2 L transplant-ineligible DLBCL interventions as a function of time leading to amortization of high-priced interventions., (© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.